Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphodiesterase type 4 (PDE4) is a family of enzymes, comprising four subtypes (PDE4A, PDE4B, PDE4C, and PDE4D), that specifically catalyze the hydrolysis of cyclic adenosine monophosphate (cAMP) [9, 18]. As cAMP is a critical second messenger in various signaling pathways, PDE4 plays a central role in regulating immune responses, neurotransmission, and smooth muscle tone [1, 8]. These enzymes are predominantly expressed in inflammatory and immune cells, as well as in the central nervous system and airway smooth muscle [1, 15]. Dysregulation of PDE4 activity is associated with chronic inflammatory diseases such as chronic obstructive pulmonary disease (COPD), asthma, psoriasis, and atopic dermatitis, as well as neurological conditions like depression and cognitive impairment [1, 4, 12]. Therapeutic targeting of PDE4 with small-molecule inhibitors, such as roflumilast and apremilast, increases intracellular cAMP levels to exert potent anti-inflammatory and bronchodilatory effects [3, 5]. However, the clinical utility of systemic PDE4 inhibitors is often limited by a narrow therapeutic window, primarily due to gastrointestinal side effects like nausea and emesis, which are thought to be mediated by the inhibition of specific PDE4 isoforms in the brain [4, 9, 17].
PDE4 inhibitors prevent the hydrolysis of cyclic adenosine monophosphate (cAMP) into 5'-adenosine monophosphate (5'-AMP) by the PDE4 enzyme family [1, 3]. This inhibition leads to increased intracellular cAMP levels, which subsequently activate protein kinase A (PKA) and exchange protein activated by cAMP (Epac) [12]. These pathways modulate gene expression and protein activity to suppress the production of pro-inflammatory cytokines (e.g., TNF-α, IL-17, IL-23) and enhance the production of anti-inflammatory mediators (e.g., IL-10), resulting in reduced inflammatory cell activation and smooth muscle relaxation [3, 12, 15].
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphodiesterase type 4 (PDE4) (PDE4).